About the job
Eikon Therapeutics is an innovative biopharmaceutical company leveraging cutting-edge technology that merges chemistry, engineering, computation, and biology to develop groundbreaking treatments for severe diseases. Our revolutionary discovery platform is founded on transformative insights from our Nobel Prize-winning founders (2014), resulting in the development of advanced microscopes that allow real-time, molecular-resolution tracking of protein movements within living cells, thereby revealing previously inaccessible classes of proteins as potential drug targets.
Position Overview
As the Executive Director of Translational Medicine and Companion Diagnostics, you will be instrumental in connecting preclinical discoveries to clinical advancements, ensuring the effective incorporation of companion diagnostics, and spearheading biomarker research strategies that support our innovative biotechnology solutions. You will collaborate extensively with cross-functional teams to lead the identification, validation, interpretation of biomarkers, and the execution of companion diagnostic assays to bolster our unique development pipeline.
Candidate Profile
The ideal candidate is a strategic visionary with a robust scientific background and demonstrated leadership experience. You will possess an in-depth understanding of drug development processes and regulatory pathways, alongside comprehensive expertise in biomarker research, validation, and interpretation, as well as experience in developing companion diagnostics. Your strategic foresight, commitment to pioneering research, and dedication to the integration of technology will drive innovative strategies, foster collaboration among diverse teams, and propel advancements in biotechnology within a dynamic, interdisciplinary environment.
This role necessitates a minimum of three days per week of onsite presence (or more as required by business needs) at our New Jersey office to ensure effective management, operational excellence, and the high-performance delivery of clinical studies while supporting anticipated significant team expansion and collaboration.

